Munich based Tubulis is working on ADCs that it believes are more durable, potent, and homogenous than others on the market currently - it has signed partnerships with Gilead and Bristol
Co-Founder and CEO Dominik Schumacher describes what he thinks can be improved on from the current generation of antibody-drug conjugates, and the science behind how Tubilis is designing its ADCs differently. He highlights the company's clinical Napi2b and 5T4 programs.
-------- Â
16:49
As the field builds on the initial success of PARP inhibitors, Artios Pharma is working on the next generation of DNA Damage Response (DDR)-based therapies - it just had clinical data on one at AACR
CEO Niall Martin walks us through the current state of this corner of drug development, and then highlights data presented at AACR last week for its ATR kinase inhibitor. As he describes, patient selection for these therapies can make a big difference.
-------- Â
19:33
Munich based ITM Radiopharma is progressing towards a first NDA in the U.S. with a robust pipeline behind it - all the while making investments in isotope manufacturing that has slowed others
CEO Andrew Cavey describes how ITM has been investing to avoid the shortages others have experienced, and explains how the supply chain works for radiopharmaceuticals. He walks us through the science behind these medicines before highlighting ITM's pipeline.
-------- Â
20:34
Munich based Ethris is developing a proprietary mRNA and lipid nanoparticle combination that is stable and allows for nasal administration or to be inhaled via nebulization
CEO Carsten Rudolph and CMO Thomas Langenickel describe the technology, which can be spray dried and shipped in a dry powder formulation, and also the clinical experience so far on the lead program in asthma.
-------- Â
15:43
Swiss Biotech Day: Geneva based Light Chain Bioscience is developing bi-specifics that integrate two light chains into its structure with the goal of having a more native format
CEO Nicolas Fischer describes the rationale of designing bi-specifics this way, and walks us through the company's programs, which mostly have a CD47 or CD28 backbone.
USA